Treatment of Frequently Relapsing or Steroid-Dependent Minimal Change Disease

Minimal change disease typically responds to initial therapy, but a clinically important subset of patients go on to relapse frequently or develop steroid dependence — a pattern that calls for a structured, evidence-based management approach.

Clinical Scenario

Most patients relapse infrequently after remission, but a significant minority will relapse frequently or become steroid-dependent. Studies report that up to 33% of patients fall into this category — with frequent relapsers comprising 11%–29% and steroid-dependent patients 14%–30% of those affected.

Treatment Approach (Overview)

Management of an active relapse in this population centres on glucocorticoid therapy to re-establish remission, followed by a structured tapering phase. The complete sequencing, agent selection, and any considerations for subsequent therapy are set out in the full protocol.

Treatment Goal

Achievement of remission of nephrotic syndrome.

Remission of nephrotic syndrome

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1038/kisup.2012.18

Most patients will relapse infrequently after remission, but a significant minority will relapse frequently or become steroid-dependent.
Up to 33% of patients will become frequent relapsers (11%–29%) or steroid-dependent (14%–30%).
Generally, FR patients who are in relapse are retreated with glucocorticoids until remission is achieved before a second-line agent is introduced.
One regimen is to administer oral prednisone at a daily dose of 1 mg/kg (maximum dose of 80 mg/d) for 4 weeks or until remission is achieved, followed by 5-mg decrements every 3–5 days to discontinuation within 1–2 months.

View source ↗